Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMNM Immunome	$9.90 -0.5%	$9.76	$5.15 ▼ $16.73	$866.10M	1.93	653,793 shs	412,503 shs
TRDA Entrada Therapeutics	$5.65 -0.5%	$6.26	$4.93 ▼ $21.79	$216.05M	-0.12	269,335 shs	117,968 shs
TRVI Trevi Therapeutics	$7.21 -9.9%	$6.89	$2.36 ▼ $8.78	$974.22M	0.58	1.79 million shs	3.27 million shs
URGN Urogen Pharma	$19.24 -1.5%	$16.89	$3.42 ▼ $21.01	$904M	1.12	1.06 million shs	882,738 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMNM Immunome	-2.07%	+3.97%	-8.21%	+11.17%	-33.53%
TRDA Entrada Therapeutics	+1.25%	+6.97%	-8.83%	-28.10%	-65.99%
TRVI Trevi Therapeutics	+7.82%	+7.82%	+4.71%	+25.79%	+174.91%
URGN Urogen Pharma	+0.21%	+1.19%	+3.39%	+392.19%	+36.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMNM Immunome	1.5996 of 5 stars	3.5	0.0	0.0	2.0	2.5	0.0
TRDA Entrada Therapeutics	3.1358 of 5 stars	3.5	3.0	0.0	3.2	2.5	0.6
TRVI Trevi Therapeutics	2.8628 of 5 stars	4.6	1.0	0.0	2.0	2.5	0.0
URGN Urogen Pharma	4.5868 of 5 stars	4.5	3.0	4.5	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMNM Immunome	3.00	Buy	$22.50	127.27% Upside
TRDA Entrada Therapeutics	3.00	Buy	$25.67	354.28% Upside
TRVI Trevi Therapeutics	3.20	Buy	$20.11	178.93% Upside
URGN Urogen Pharma	3.00	Buy	$32.00	66.32% Upside

Current Analyst Ratings Breakdown

Latest TRDA, TRVI, URGN, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	IMNM Immunome	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/22/2025	IMNM Immunome	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
8/21/2025	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$18.00
8/18/2025	URGN Urogen Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$36.00
8/11/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
8/8/2025	TRDA Entrada Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMNM Immunome	$9.04M	95.32	N/A	N/A	$3.09 per share	3.20
TRDA Entrada Therapeutics	$210.78M	1.02	$1.58 per share	3.58	$9.98 per share	0.57
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.63 per share	N/A
URGN Urogen Pharma	$90.40M	9.85	N/A	N/A	($2.02) per share	-9.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	11/12/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	-$1.78	N/A	N/A	N/A	-92.30%	-17.81%	-14.55%	11/4/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.42	N/A	N/A	N/A	N/A	-41.44%	-38.21%	11/5/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-59.38%	11/5/2025 (Estimated)

Latest TRDA, TRVI, URGN, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.82	-$1.05	-$0.23	-$1.05	$23.06 million	$24.22 million
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million
8/6/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	-$1.04	-$0.18	-$1.04	$8.17 million	$1.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMNM Immunome	N/A	12.13	12.13
TRDA Entrada Therapeutics	N/A	18.64	18.64
TRVI Trevi Therapeutics	N/A	22.42	22.42
URGN Urogen Pharma	N/A	4.14	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMNM Immunome	44.58%
TRDA Entrada Therapeutics	86.39%
TRVI Trevi Therapeutics	95.76%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
IMNM Immunome	7.69%
TRDA Entrada Therapeutics	8.11%
TRVI Trevi Therapeutics	18.30%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMNM Immunome	40	87.04 million	80.35 million	Optionable
TRDA Entrada Therapeutics	110	38.04 million	34.95 million	Optionable
TRVI Trevi Therapeutics	20	121.78 million	99.49 million	Optionable
URGN Urogen Pharma	200	46.26 million	44.09 million	Optionable

TRDA, TRVI, URGN, and IMNM Headlines

Recent News About These Companies

Partners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGN

August 24, 2025 | marketbeat.com

UroGen Pharma to Present at Upcoming Investor Conferences

August 21, 2025 | globenewswire.com

Fox Run Management L.L.C. Takes Position in Urogen Pharma $URGN

August 21, 2025 | marketbeat.com

Piper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight Recommendation

August 20, 2025 | msn.com

Piper starts ‘underestimated’ UroGen Pharma with an Overweight

August 19, 2025 | msn.com

UroGen Pharma initiated with an Overweight at Piper Sandler

August 18, 2025 | msn.com

UroGen Pharma: Targeting Profits In 2027

August 18, 2025 | seekingalpha.com

Oak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)

August 17, 2025 | marketbeat.com

Q3 EPS Estimates for Urogen Pharma Reduced by HC Wainwright

August 16, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares

August 15, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Brokerages

August 14, 2025 | marketbeat.com

17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners Ltd

August 13, 2025 | marketbeat.com

UroGen Pharma’s Earnings Call: Achievements and Challenges

August 13, 2025 | msn.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

HC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock Price

August 12, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

August 10, 2025 | finance.yahoo.com

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8, 2025 | marketbeat.com

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...

August 8, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, TRVI, URGN, and IMNM Company Descriptions

Immunome NASDAQ:IMNM

$9.90 -0.05 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$10.06 +0.16 (+1.67%)

As of 07:49 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Entrada Therapeutics NASDAQ:TRDA

$5.65 -0.03 (-0.53%)

Closing price 04:00 PM Eastern

Extended Trading

$5.65 0.00 (0.00%)

As of 06:49 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Trevi Therapeutics NASDAQ:TRVI

$7.21 -0.79 (-9.88%)

Closing price 04:00 PM Eastern

Extended Trading

$7.26 +0.04 (+0.62%)

As of 07:14 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Urogen Pharma NASDAQ:URGN

$19.24 -0.30 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$19.30 +0.06 (+0.31%)

As of 07:50 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time